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T cell depletion can prevent hypertension in experimental animals. What is the nature of T cell activation in
hypertension? In this issue of Immunity, Carnevale et al. (2014) implicate PlGF signaling in a reservoir of
splenic T cells.Most immunologists do not list ‘‘hyperten-
sion’’ in their keywords. Scientists inter-
ested in immunity usually focus on he-
matopoietic cells, the cellular responses
to infection and products of sterile injury,
and the genetic mechanisms underlying
signal transduction. But there are notable
exceptions. The history of immunological
approaches to blood pressure has pro-
duced extremely impactful results.
One example is monoclonal anti-tumor
necrosis factor (TNF) antibody therapies,
now used by millions of autoimmune and
autoinflammatory disease patients. The
first experiments using monoclonal anti-
TNF antibodies as an experimental thera-
peutic agent were to prevent low blood
pressure (‘‘shock’’) in baboons infected
with lethal quantities of E. coli (Tracey
et al., 1987). Administration ofmonoclonal
anti-TNF prevented the drop in blood
pressure mediated by TNF. This insight
prompted the pharmaceutical manu-
facturing of TNF mAb. The availability of
these clinical reagents was pivotal to sub-
sequent clinical use in rheumatoid arthritis
and inflammatory bowel disease.
In the United States, 67 million adults,
many of them immunologists, have high
blood pressure. Hypertension is a contrib-
uting factor in the deaths of 350,000, with
an attributed nationwide cost basis
exceeding $45 billion, annually. Despite
the enormity of this health problem, themechanisms underlying hypertension are
at best incompletely understood. Under-
lying mechanisms for hypertension can
be established in only 10% of cases.
The remainder is classified as ‘‘essential
hypertension,’’ meaning chronically ele-
vated blood pressure from unknown
causes. Incomplete pathogenic knowl-
edge underlies the inadequate efficacy
of many, if not most, current therapies.
It certainly makes a compelling argu-
ment that new research approaches are
needed. Immunology research may open
the door to new mechanisms.
As reviewed in much greater length and
detail elsewhere, there have been dozens
of studies implicating T lymphocytes and
other hematopoietic cells in the patho-
genesis of essential hypertension in hu-
mans, and in experimental models of
chronic hypertension. Dating back to the
1960s, Okuda and Grollman induced hy-
pertension in naive rats by passively
transferring lymphocytes harvested from
donor rats rendered hypertensive fol-
lowing experimentally induced renal in-
farction (Okuda and Grollman, 1967).
More recently, a seminal study fromDavid
Harrison’s group reported that Rag1/
mice failed to develop hypertension in
response to chronic exposure to angio-
tensin II, a standard laboratory model of
chronic hypertension in rodents (Guzik
et al., 2007). Passive transfer of T cells,but not B cells, restored the hypertensive
response to angiotensin II infusion. A ma-
jor question is what factor(s) activates
T cells to mediate hypertension?
In this issue of Immunity, Carnevale et al.
(2014) observed that placental growth fac-
tor (PlGF)-deficient mice are protected
against hypertension during angiotensin II
infusion. PlGF, a member of the angiogen-
esis family of factors related to vascular
endothelial growth factor (VEGF), is ex-
pressed by cells from the immune and
cardiovascular systems, but whether it
contributed to T cell activation in hyperten-
sion was previously unknown. PlGF-defi-
cient animals were also protected against
T cell mediated inflammation and tissue
injury in the heart, kidney, and aorta that
occurs following angiotensin II infusion.
Surprisingly, the spleen is the reservoir of
these pathogenic T cells. Release of these
cells from spleen during angiotensin II
infusion is controlled by adrenergic neural
signals to spleen that converge on PlGF.
Angiotensin II infusion increased the
expression of tyrosine hydroxylase, the
rate-limiting enzyme in the biosynthesis
of norepinephrine by adrenergic neurons,
and norepinephrine levels in spleen. Abla-
tion of the adrenergic splenic nerve by sur-
gical removal of the celiac ganglion pre-
vented recruitment of pathogenic T cells
from the spleen to the aorta and kidney.
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Figure 1. Neural Regulation of Hypertension Mediated by Splenic T Cells
Neural signals to spleen culminate in norepinephrine release and increased production of PlGF. This
enhances expression of Timp3 in T cells that are in turn released from the splenic reservoir. They travel
to the aorta, other vessels, and kidney, producing hypertension and tissue damage.
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Previewsand tissue injury was accomplished by
simply removing the spleen. Reimplanted
spleen from WT donors restored the hy-
pertensive response to angiotensin II.
But mice reimplanted with spleen from
PlGF-deficient donors continued to be
protected against the hypertensive effects
of angiotensin II. The molecular mecha-
nism of PlGF-mediated T cell egress
from spleen is by Sirt1-p53 nucleus pro-
teins, because chronic administration of
the selective inhibitor Ex-527 and genetic
silencing of Sirt1 in PlGF-deficient spleno-
cytes restored the hypertensive response
to angiotensin II. These results are highly
significant because they identify previ-
ously unrecognizedmechanisms of hyper-
tension (Figure 1).
Should we be surprised that immune
signaling and cell-trafficking studies
contribute to basic mechanisms of blood
pressure regulation? Yes and no. ‘‘Yes,’’
if your approach to immunology is
restricted to how information is pro-
cessed by hematopoietic cells to produce
a memory of the events that can be
recalled at a later date. ‘‘No,’’ if your
approach to immunology embraces the
evolutionary role of the immune system
as a major sensory organ on the front
line detecting changes in the milieu inter-
ieur. The ultimate purpose of visceral sen-
sory pathways is tomaintain physiological
homeostasis. This physiological role of
the immune system overlaps the sensory
nervous system.674 Immunity 41, November 20, 2014 ª2014The body goes to almost absurd
lengths to maintain blood pressure within
a fairly narrow range. Hematopoietic cells
sense all of the factors that influence
blood pressure-exsanguination, salt
loading, and even angiotensin II infu-
sions—and respond by altering their im-
mune functions, metabolism, and gene
expression. Sensory neuronal activity is
also changed by these factors. Viewed
from the evolutionary perspective, the
nervous and immune systems developed
together on the front line of sensory input.
Maintenance of stable blood pressure
occurs by the integrated output of both
systems.
These results also highlight an opportu-
nity for immunologists. Recent advances
have revealed neural circuits that modu-
late lymphocytes. Mapping the genetic,
molecular, and neurophysiological basis
of the inflammatory reflex also converged
on the spleen (Rosas-Ballina et al., 2011;
Rosas-Ballina et al., 2008). In this proto-
typical circuit, action potentials are trans-
mitted in the vagus nerve to the celiac
ganglion, the origin of the splenic nerve
mentioned above (Andersson and Tracey,
2012). Activation of adrenergic splenic
neurons regulate a T cell subset in splenic
white pulp. These T cells are stimulated by
norepinephrine signaling via beta adren-
ergic receptors to release acetylcholine,
a neurotransmitter that signals via alpha7
nicotinic acetylcholine receptors ex-
pressed by red pulp and marginal zoneElsevier Inc.macrophages. The net effect of the action
potentials originating in the vagus nerve is
to inhibit spleen macrophage production
of TNF and other cytokines.
The present findings suggest that we
are at the early stages of understanding
the specificity and sensitivity of neural cir-
cuits that culminate in spleen to regulate
lymphocytes. It is possible to regulate
the inflammatory reflex using implanted
nerve stimulators that inhibit TNF. Early
clinical trials indicate that it might be
possible to treat rheumatoid arthritis,
even in patients refractory to other ther-
apy. Might it be possible to develop phar-
macological or nerve-stimulating strate-
gies to target the PlGF pathway as a
treatment for hypertension? Perhaps.
There are a number of other important
opportunities to further purse this mecha-
nism. What is the T cell receptor for PlGF
signaling? How does norepinephrine
modulate P1GF release or activity? What
is the molecular basis for T cell release
from the splenic reservoir? And how do
PlGF-activated T cells mediate damage
in blood vessels and kidney? Will it be
possible to develop PlGF antibodies to
treat hypertension? These and other an-
swers could impact millions of patients.REFERENCES
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